KURA
Price:
$19.29
Market Cap:
$1.48B
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a ...[Read more]
Industry
Biotechnology
IPO Date
2015-09-16
Stock Exchange
NASDAQ
Ticker
KURA
According to Kura Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.73. This represents a change of 19.04% compared to the average of -7.33 of the last 4 quarters.
The mean historical PE Ratio of Kura Oncology, Inc. over the last ten years is -7.48. The current -8.73 PE Ratio has changed 11.58% with respect to the historical average. Over the past ten years (40 quarters), KURA's PE Ratio was at its highest in in the June 2016 quarter at -1.89. The PE Ratio was at its lowest in in the December 2014 quarter at -1967.47.
Average
-7.48
Median
-7.02
Minimum
-19.38
Maximum
-0.19
Discovering the peaks and valleys of Kura Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.82%
Maximum Annual PE Ratio = -0.19
Minimum Annual Increase = -99.99%
Minimum Annual PE Ratio = -19.38
Year | PE Ratio | Change |
---|---|---|
2023 | -6.90 | 12.92% |
2022 | -6.11 | -14.56% |
2021 | -7.15 | -63.11% |
2020 | -19.38 | 112.20% |
2019 | -9.13 | 11.75% |
2018 | -8.17 | -18.53% |
2017 | -10.03 | 150.62% |
2016 | -4.00 | 8.56% |
2015 | -3.69 | 1.82% |
2014 | -0.19 | -99.99% |
The current PE Ratio of Kura Oncology, Inc. (KURA) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.72
5-year avg
-9.74
10-year avg
-7.48
Kura Oncology, Inc.’s PE Ratio is less than Protagonist Therapeutics, Inc. (14.97), greater than Merus N.V. (-18.45), less than Replimune Group, Inc. (-3.26), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), less than KalVista Pharmaceuticals, Inc. (-4.02), greater than Crinetics Pharmaceuticals, Inc. (-15.40), less than Theseus Pharmaceuticals, Inc. (-3.19), less than Viridian Therapeutics, Inc. (-3.95), greater than Gracell Biotechnologies Inc. (-12.26), less than Monte Rosa Therapeutics, Inc. (-3.11), less than Design Therapeutics, Inc. (-5.23), less than Erasca, Inc. (-3.94), less than Cogent Biosciences, Inc. (-4.58), greater than Larimar Therapeutics, Inc. (-8.80), greater than Kiniksa Pharmaceuticals, Ltd. (-173.03), less than Day One Biopharmaceuticals, Inc. (-7.39), less than Inozyme Pharma, Inc. (-3.48), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Syndax Pharmaceuticals, Inc. (-6.17),
Company | PE Ratio | Market cap |
---|---|---|
14.97 | $2.44B | |
-18.45 | $3.41B | |
-3.26 | $708.49M | |
-17.73 | $8.19B | |
-4.02 | $531.63M | |
-15.40 | $4.03B | |
-3.19 | $181.50M | |
-3.95 | $900.21M | |
-12.26 | $989.87M | |
-3.11 | $349.21M | |
-5.23 | $264.42M | |
-3.94 | $807.96M | |
-4.58 | $1.15B | |
-8.80 | $513.64M | |
-173.03 | $1.78B | |
-7.39 | $1.25B | |
-3.48 | $312.42M | |
-1.08 | $210.48M | |
-6.17 | $1.63B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kura Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kura Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Kura Oncology, Inc.'s PE Ratio?
How is the PE Ratio calculated for Kura Oncology, Inc. (KURA)?
What is the highest PE Ratio for Kura Oncology, Inc. (KURA)?
What is the 3-year average PE Ratio for Kura Oncology, Inc. (KURA)?
What is the 5-year average PE Ratio for Kura Oncology, Inc. (KURA)?
How does the current PE Ratio for Kura Oncology, Inc. (KURA) compare to its historical average?